secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001493152-24-001905
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech opens enrollment in Phase 1b/2 trial of Ampligen + Imfinzi for pancreatic cancer
--------------------------------------------------------------------------------

- Enrollment open at Erasmus MC for DURIPANC study combining Ampligen + AstraZeneca's Imfinzi; dosing expected soon.
- Phase 1b portion will enroll up to 18 subjects; Phase 2 up to 25 patients with metastatic pancreatic ductal adenocarcinoma.
- Ampligen dose escalation from 200 mg to 400 mg IV twice weekly; durvalumab 1500 mg IV every 4 weeks for up to 48 weeks.
- Primary objectives: safety in Phase 1b, clinical benefit rate in Phase 2.
- AIM recently received a U.S. patent for using Ampligen in combination with an anti-PD-L1 antibody.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315224001905/0001493152-24-001905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315224001905/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-001905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer